NasdaqGS:TWSTBiotechs
Is Twist Bioscience’s (TWST) New ATM Program Quietly Reframing Its AI Genomics Investment Story?
In June 2026, Twist Bioscience filed an omnibus shelf registration covering common and preferred stock, debt, warrants, and units, and separately registered a US$200,000,000 at-the-market follow-on equity offering of its common shares.
At the same time, Twist drew fresh attention from Osterweis Opportunity Fund for its role in liquid biopsy and as an outsourced wet lab for AI genomics, underscoring how its synthetic DNA platform is being used at the intersection of genomics and artificial...